A couple days ago it was announced Biological E's coronavirus vaccine candidate achieved emergency use approval in India... Using $DVAX adjuvant, as do valneva, clover and others... Millions of orders on the way... It's down now but recent analyst upgrade to $28... Hoping to skyrocket soon!

News this morning about $ABUS developing pill for COVID and future coronaviruses, on top of recent win defending LNP patent against $MRNA … this just seems like a gold mine to me.

(not to mention core business of curing Hep-B)

Giving up on holding this bag to free up some cash... RNAi (e.g. $ABUS $ARWR ) seem to have more promise than DNA editing in the near term, but I'm no expert.

Buying the dip!

$DVAX has 4 large international COVID partners (Valneva, Clover, Medigen, Bio-E), some on the cusp of approval, with inactivated virus which is more effective against new variants, dependent on DVAX's proprietary adjuvant.

DVAX has the only 2 dose Hep-B vaccine on the market and has been gaining market share quarter after quarter.

DVAX has cash reserves close to 400 million - the recent dip after earnings were misleading as they are actually profitable.

$ABUS owns patent on LNP technology behind basically all mRNA vaccines. Today $MRNA lost appeal against previous patent court ruling against them. Go Arbutus! 🎉🍿